Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02538536

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial

Official title:
A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Summary

This is a Phase 2, open-label, single-arm study of the safety and tolerability of PBI-4050 800 mg daily oral administration in 40 adult patients with IPF.

Clinical Trial Description

This Phase 2 multi-centre study will be performed by 6 Canadian sites. It is an open-label, single-arm study in patients with Idiopathic Pulmonary Fibrosis (IPF) aged 40 years and older.

The duration of study participation is approximately 20 weeks for each patient and comprises 6 study visits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02538536
Study type Interventional
Source ProMetic BioSciences Inc.
Contact
Status Completed
Phase Phase 2
Start date July 2015
Completion date January 2017
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04497831 - Morphine for Dyspnea in Pulmonary Fibrosis Phase 3
Recruiting NCT05119972 - Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） Phase 1/Phase 2
Completed NCT01718990 - Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Completed NCT00162760 - Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Phase 2
Terminated NCT04589260 - TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT04069143 - A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327 Phase 1
Completed NCT03050255 - Short-term Effects of Supplemental Oxygen in Patients With IPF N/A
Terminated NCT02013700 - Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) Phase 1
Recruiting NCT04598919 - Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Phase 1/Phase 2
Completed NCT03981094 - A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants Phase 1
Completed NCT02758808 - Pulmonary Fibrosis Foundation Patient Registry
Not yet recruiting NCT05387785 - Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis Phase 1
Recruiting NCT05938920 - Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT01371305 - STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Withdrawn NCT03720483 - Inhaled NAC in Treatment of IPF Phase 1/Phase 2
Recruiting NCT03478553 - The Genetics of Pulmonary Fibrosis
Recruiting NCT05975983 - Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03650075 - To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers Phase 1
Completed NCT03832946 - A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT02874989 - Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial Phase 1